Project Grant R01CA300245
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$681K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $703,410 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, awarded on January 16, 2025, supports a comprehensive research program aimed at understanding and disrupting the adenocarcinoma-to-squamous-cell transition, a cellular plasticity mechanism that enables resistance to KRAS inhibitor therapies in non-small cell lung cancer.
The research involves conducting a...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $1,343,188 in funding to The Regents of the University of California, San Francisco to conduct research aimed at understanding the molecular and cellular mechanisms underlying the development of drug resistance in squamous cell carcinomas.
The key objectives of this 5-year research project are to: 1) Use single-cell analyses to identify tumor cell populations with high...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $695,916 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel nSMase2 inhibitors for enhancing immune checkpoint inhibitor (ICI) response in cancer treatment.
The grant aims to synthesize and test analogs of the nSMase2 inhibitor PDDC to improve its potency, solubility, and pharmacokinetics....
This $269,280 Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to develop a novel targeted therapeutic approach for cancers driven by the K-RAS(G12C) mutation. The key objectives are to:
Determine the selectivity of cytotoxic jerantinine alkaloid-based compounds for covalent labeling and degradation of the K-RAS(G12C) oncogenic protein. This will involve synthesizing a library of hybrid molecules and evaluating...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $735,635 to New York University School of Medicine to investigate cellular mechanisms underlying resistance to KRAS inhibitors in lung adenocarcinoma (LUAD). The research aims to:
Identify LUAD differentiation states, such as an alveolar type 1 (AT1)-like state and a squamous transition state, that confer resistance to KRAS inhibitors. 2) Utilize genetically engineered mouse models...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support research by the University of Texas MD Anderson Cancer Center to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer. The $267,527 award, effective January 1, 2025 through December 31, 2026, will fund experiments to: 1) determine how SMARCA4 mutations confer resistance to KRAS G12C inhibitors, 2) develop SMARCA2 degrader compounds to...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), provides $607,580 to The Regents of the University of California, San Francisco (UCSF) to advance cancer research. The key objectives are to: 1) identify molecular markers that distinguish tumor vasculature from normal vasculature, 2) determine if inhibition of the marker ENPEP promotes favorable outcomes in glioblastoma (GBM) mouse models, and 3) develop...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $530,786 to The Leland Stanford Junior University to conduct research focused on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The key objectives are to:
Determine how distinct neuroendocrine SCLC cell states dictate the choice to die by apoptosis versus ferroptosis, focusing on the role of the GCN2/ATF4 amino acid sensing pathway and...
This $676,567 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The grant supports a 5-year research project to systematically evaluate the effectiveness of a transforming growth factor beta (TGFβ)-targeted radiopharmaceutical therapy (RPT) as a potential tumor-agnostic cancer treatment. The project aims to radiolabel a validated TGFβ-neutralizing...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...